Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091266 | 0.96 | LMNA (0.44) | LMNAGPR27TRPV1LARS1PPARA | |
| SCHEMBL15000148 | 0.90 | LARS1 (0.45) | LMNALARS1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL3093901 | 0.90 | MMP9 (0.46) | LMNAGPR27LARS1PPARAKAT6A | |
| SCHEMBL3102970 | 0.90 | MMP9 (0.46) | LMNAGPR27LARS1PPARAKAT6A | |
| SCHEMBL3093062 | 0.88 | NPC1 (0.48) | LMNALARS1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL14999964 | 0.86 | KAT6A (0.47) | LARS1KAT6AKDM4E | |
| SCHEMBL15000037 | 0.86 | LARS1 (0.49) | LMNALARS1KDM4E | |
| SCHEMBL3089105 | 0.85 | LARS1 (0.40) | LMNALARS1KAT6AKDM4E | |
| SCHEMBL3088704 | 0.85 | LARS1 (0.40) | LMNAGPR27LARS1KAT6AKDM4E | |
| SCHEMBL3090792 | 0.84 | NPC1 (0.51) | LMNAGPR27LARS1KAT6ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | LMNA 3803/4885GPR27 141/4885TRPV1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.